Ainos (NASDAQ:AIMD) Shares Up 1.4% – Here’s What Happened

Posted by ABMN Staff on Jan 23rd, 2026

Ainos, Inc. (NASDAQ:AIMD – Get Free Report)’s stock price rose 1.4% during mid-day trading on Thursday . The stock traded as high as $1.8928 and last traded at $1.8760. Approximately 11,109 shares traded hands during trading, a decline of 35% from the average daily volume of 17,124 shares. The stock had previously closed at $1.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ainos in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on AIMD

Ainos Stock Performance

The company has a current ratio of 2.96, a quick ratio of 2.67 and a debt-to-equity ratio of 1.10. The firm has a market cap of $9.02 million, a PE ratio of -0.47 and a beta of 2.45. The stock’s 50 day moving average price is $2.01 and its 200 day moving average price is $2.89.

Ainos (NASDAQ:AIMD – Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.64) earnings per share for the quarter. The company had revenue of $0.00 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ainos stock. Two Sigma Investments LP purchased a new position in Ainos, Inc. (NASDAQ:AIMD – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned approximately 0.48% of Ainos at the end of the most recent quarter.

Ainos Company Profile

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.